Denosumab in bone marrow oedema syndrome. Response to Letter to the Editor of Injury
Standard
Denosumab in bone marrow oedema syndrome. Response to Letter to the Editor of Injury. / Rolvien, Tim; Schmidt, Tobias; Barvencik, Florian; Amling, Michael.
In: INJURY, Vol. 48, No. 10, 10.2017, p. 2368.Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research
Harvard
Rolvien, T, Schmidt, T, Barvencik, F & Amling, M 2017, 'Denosumab in bone marrow oedema syndrome. Response to Letter to the Editor of Injury', INJURY, vol. 48, no. 10, pp. 2368. https://doi.org/10.1016/j.injury.2017.07.029
APA
Rolvien, T., Schmidt, T., Barvencik, F., & Amling, M. (2017). Denosumab in bone marrow oedema syndrome. Response to Letter to the Editor of Injury. INJURY, 48(10), 2368. https://doi.org/10.1016/j.injury.2017.07.029
Vancouver
Rolvien T, Schmidt T, Barvencik F, Amling M. Denosumab in bone marrow oedema syndrome. Response to Letter to the Editor of Injury. INJURY. 2017 Oct;48(10):2368. https://doi.org/10.1016/j.injury.2017.07.029
Bibtex
@article{8b7c9adf2cf64ef38cdf8acc906a1fc2,
title = "Denosumab in bone marrow oedema syndrome. Response to Letter to the Editor of Injury",
keywords = "Letter",
author = "Tim Rolvien and Tobias Schmidt and Florian Barvencik and Michael Amling",
note = "Letter",
year = "2017",
month = oct,
doi = "10.1016/j.injury.2017.07.029",
language = "English",
volume = "48",
pages = "2368",
journal = "INJURY",
issn = "0020-1383",
publisher = "Elsevier Limited",
number = "10",
}
RIS
TY - JOUR
T1 - Denosumab in bone marrow oedema syndrome. Response to Letter to the Editor of Injury
AU - Rolvien, Tim
AU - Schmidt, Tobias
AU - Barvencik, Florian
AU - Amling, Michael
N1 - Letter
PY - 2017/10
Y1 - 2017/10
KW - Letter
U2 - 10.1016/j.injury.2017.07.029
DO - 10.1016/j.injury.2017.07.029
M3 - Other (editorial matter etc.)
C2 - 28784253
VL - 48
SP - 2368
JO - INJURY
JF - INJURY
SN - 0020-1383
IS - 10
ER -
